Aboulia: Neurobehavioural dysfunction of dopaminergic system?

Medical Hypotheses

Volumn 54, Issue 4, 2000, Pages 523-530

  Al Adawi, S ^a   Dawe, G S ^b   Al Hussaini, A A ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT;

APATHY; DOPAMINERGIC SYSTEM; FOREBRAIN; FRONTAL CORTEX; HUMAN; MESENCEPHALON; MOTIVATION; NEGATIVE SYNDROME; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION; VENTRAL TEGMENTUM;

EID: 0034027406     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0890     Document Type: Article

References (116)

1. Jastrow J. Will (disorders of). Baldwin J. M. Dictionary of Philosophy and Psychology, 1901;MacMillan, London.
2. Fisher C. M. Honoured guest presentation: abulia minor vs. agitated behavior. Clin Neurosurg. 31:1983;9-31.
3. Berrios G. E., Gili M. Abulia and impulsiveness revisited: a conceptual history. Acta Psychiatr Scand. 92:1995;161-167.
4. Drubach D. A., Zeilig G., Perez J., Peralta L., Makley M. Treatment of abulia with Carbidopa/Levadopa. Journal of Neurologic Rehabilitation. 9:1995;151-155.
5. Caplan L. R., Schmahmann J. D., Kase C. S. Caudate infarcts. Arch Neurol. 47:1990;133-143.
6. Marin R. S. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 3:1991;243-254.
7. Laplane D. Loss of psychic self-activation. Rev Neurol (Paris). 146:1990;397-404.
8. Naville F. Les complications des sequelles mentales de l'encephalite epidemique. L'encephale. 17:1922;369-375.
9. Hassler R. Extrapyramidal-motorische systeme und Erkrankungen. Handbuck der Innerin Medezin, 1953;Springer, Berlin. p. 676-904.
10. Arieti S. Schizophrenia: the manifest symptomatology, the psychodynamic and formal mechanisms. Arieti S. American Handbook of Psychiatry, 1959;455-484 Basic Books Inc, New York.
11. Ribot, T. La Psychologie des Sentiments. Felix Alcan, Paris, 1886.
12. Cutting J. The role of right hemisphere disfunction in psychiatric disorders. Br J Psychiatry. 180:1992;583-588.
13. Bermanzohn P. C., Siris S. G. Akinesia - a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. Compr Psychiatry. 33:1992;221-232.
14. Cairns H., Oldfied R. C., Pennybacker J. B., Whitteridge D. Akinetic mutism with an epidermoid cyst of the 3rd ventricle. Brain. 64:1941;273-290.
15. Trillet M., Croisile B., Tourniaire D., Schott D. Disorders of voluntary motor activity and lesions of caudate nuclei. Rev Neurol Paris. 146:1990;338-344.
16. Blum K., Cull J. G., Braverman E. R., Comings D. E. Reward deficiency syndrome. Am Sci. 84:1996;132-145.
17. Willner P. Animal-models of depression - validity and applications. Adv Biochem Psychopharmacol. 49:1995;19-41.
18. Trovero F., Blanc G., Herve D., Vezina P., Glowinski J., Tassin J. P. Contribution of an alpha-1-adrenergic receptor subtype to the expression of the ventral tegmental area syndrome. Neuroscience. 47:1992;69-76.
19. Van Reekum R., Bayley M., Garner S., Burke I. M., Fawcett S., Hart A., Thompson W. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj. 9:1995;49-53.
20. Alexander G. E., DeLong M. R., Strick P. L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 9:1986;357-381.
21. Middleton F. A., Strick P. L. Basal ganglia and cerebellar output influences non-motor function. Mol Psychiatry. 1:1996;429-433.
22. Baddeley A., Wilson B. Frontal amnesia and the Dysexecutive Syndrome. Brain Cogn. 7:1988;212-230.
23. Starkstein S. E., Fedoroff J. P., Price T. R., Leiguarda R., Robinson R. G. Apathy following cerebrovascular lesions. Stroke. 24:1993;1625-1630.
24. Galynker I. I., Levinson I., Miner C., Rosenthal R. Negative symptoms in patients with basal ganglia strokes. Neuropsychiatry Neuropsychol Behav Neurol. 8:1995;113-117.
25. Kaelin D. L., Cifu D. X., Matthies B. Methylphenidate effect on attention deficit in the acutely brain-injured adult. Arch Phys Med Rehabil. 77:1996;6-9.
26. Brown P., Marsden C. D. What do the basal ganglia do? Lancet. 351:1998;1801-1804.
27. Masterman D. L., Cummings J. L. Frontal-subcortical circuits: the anatomical basis of executive, social and motivated behaviours. J Psychopharmacol. 11:1997;107-114.
28. Robbins T. W., Everitt B. Neurobehavioural mechanism of reward and motivation. Curr Opin Neurobiol. 6:1996;228-236.
29. Watanabe M. Reward expectancy in primate prefrontal neurons. Nature. 382:1996;629-632.
30. Saint-Cyr J. A., Taylor A. E., Trepanier L., Lang A. E. The caudate nucleus: head ganglion of the habit system. Vallar G., Wallesch C. Neuropsychological Impairments Associated with subcortical lesions. 1992;204-226 Oxford University Press, Oxford.
31. Fibiger, H. C. Phillips, A. G. Role of catecholamine transmitters in brain reward systems: implications for the neurobiology of affect. Angel, J.Oreland, L. Brain Reward Systems and Abuse: Seventh International Berzelius, 1987. Symposium. New York, Raven Press, 1987, 61, 74.
32. Al-Adawi S., Powell J. H., Greenwood R. J. Motivational deficits after brain injury: a neuropsychological approach using new assessment techniques. Neuropsychology. 12:1998;115-124.
33. Powell J. H., Al-Adawi S., Morgan J., Greenwood R. J. Motivation deficits after brain injury: effects of bromocriptine in 11 patients. J Neurol Neurosurg Psychiatry. 60:1996;416-421.
34. Narabayashi H. Pallidotomy revisited. Analysis of posteroventral pallidotomy. Stereotact Funct Neurosurg. 69:1997;54-61.
35. Mogenson G. J., Jones D. L., Yim C. Y. From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol. 14:1980;69-97.
36. Mrabet A., Hammouda I. M. B., Abroug Z., Smiri W., Haddad A. Akinetic mutism and abulia - Clinical expression of a reticulo-cortical integration defect. Rev Neurol. 151:1995;359.
37. Marshall J. F., Teitelbaum P. Further analysis of sensory inattention following lateral hypothalamus damage in rats. J Physiol Psychol. 86:1974;375-395.
38. Bindra D. A motivational view of learning, performance and behavior modification. Psychol Rev. 81:1974;199-213.
39. Lader M. Neuroleptic-induced deficit syndrome: old problem, new challenge. J Pharmacol. 7:1993;392-393.
40. Gallistel C. R., Karras D. Pimozide and amphetamine have opposing effects on the reward summation function. Pharmacol Biochem Behav. 20:1984;73-77.
41. Koob G. F., Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 278:1997;52-58.
42. Mortimer, W. G. History of Coca. San Francisco, Fitz Hugh Ludlow Memorial Library, 1974.
43. Kiyatkin E. A. Dopamine mechanism of cocaine addiction. Int J Neurosci. 78:1994;75-101.
44. Fowler J. S., Volkow N. D., Wang G. J. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 379:1996;733-736.
45. Al-Adawi S., Powell J. The influence of smoking on reward responsiveness and cognitive functions: a natural experiment. Addiction. 92:1997;1773-1782.
46. Brower K. J., Maddahian E., Blow F. C., Beresford T. P. A comparison of self-reported symptoms and DSM-III-R criteria for cocaine withdrawal. Am J Drug Alcohol Abuse. 14:1988;347-356.
47. Harris G., Aston-Jones G. Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome. Nature. 371:1994;155-157.
48. Weiss F., Markou A., Lorang M. T., Koob G. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access. Brain Res. 593:1992;314-318.
49. Dackis C. A., Gold M. S. Bromocriptine as treatment of cocaine abuse. Lancet. 1:1985;1151-1152.
50. Al-Adawi S., Powell J., Greenwood R. Motivation deficit following brain injury. J Psychopharmacol. 8:1994;AS28.
51. Bhatia K. P., Marsden C. D. The behavioral and motor consequences of focal lesions of the basal ganglia in man. Brain. 117:1994;859-876.
52. Cummings, J. L. Clinical Neuropsychiatry. New York, Grune and Stratton, 1985.
53. Blumer D., Benson D. F. Personality changes with frontal and temporal lobe lesion. Blumer D., Benson D. F. Psychiatric Aspects of Neurologic Disease. 1975;151-169 Grune and Stratton, New York.
54. Eslinger P. J., Gratton L. M. Frontal lobe and frontal-striatal substrate for different forms of human cognitive flexibility. Neuropsychologia. 31:1993;17-28.
55. Ackermann H., Ziegler W. Akinetic mutism-a review of the literature. Fortschr Neurol Psychiatr. 63:1995;59-67.
56. Bareggi S. R., Porta M., Selenati A. Homovanillic acid and 5-hydroxyindol acetic acid in the CSF patients after severe head injury. Eur Neurol. 13:1975;545-554.
57. Vecht C. J., Van Woerkom T. C. A. M., Teelken A. W., Minderhoud J. M. Homovanillic acid and 5-hydroxyindoleascetic acid cerebro-spinal fluid levels. Arch Neurol. 32:1975;792-797.
58. Yang S. Y., Zhang S., Wang M. L. Clinical significance of admission hyperglycaemia and factors related to it in patients with acute severe head injury. Surg Neurol. 44:1995;373-377.
59. Eames P. The use of Sinement and bromocriptine. Brain Inj. 3:1989;319-320.
60. Barrett K. Treating organic abulia with bromocriptine and lisuride: four case studies. J Neurol Neurosurg Psychiatry. 54:1991;718-721.
61. Kraepelin, E. Die Erscheinungsformen des Irresciens. Themes and Variation in European Psychiatry, S. R. HirschM. Shepherd, 1974, Bristol, John Wright, 1920.
62. Ellenbroek B. A., Willemen A. P., Cools A. R. Are antagonists of dopamine D1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study in Java monkeys. Neuropsychopharmacology. 2:1989;191-199.
63. Dixon A. K., Huber C., Lowe D. A. Clozapine promotes approach-oriented behavior in male mice. J Clin Psychiatry. 55:1994;4-7.
64. Andreasen, N. C. 1989, Neural mechanism of negative symptoms. Br J Psychiatry Suppl. 1989, 7, 93, 98.
65. Takigawa M., Maeda H., Ueyama K., Tominaga H., Matsumoto K. A dual approach to self-stimulation and locomotor trace affected by chronic methamphetamine treatment for an animal model of schizophrenia. Can J Physiol Pharmacol. 71:1993;321-325.
66. Bornstein R. A., Schwarzkopf S. B., Olson S. C., Nasrallah H. A. Third-ventricle enlargement and neuropsychological deficit in schizophrenia. Biol Psychiatry. 31:1992;954-961.
67. Crow T. J. Brain changes and negative symptoms in schizophrenia. Psychopathology. 28:1995;18-21.
68. Chouinard G., Jones B. D. Schizophrenia as a dopamine deficiency disease. Lancet. 2:1978;99-100.
69. Martinot J. L., Paillere-Martinot M. I., Loc'h C. Central D2 receptors and negative symptoms of schizophrenia. Br J Psychiatry. 164:1994;27-32.
70. Okubo Y., Suhara T., Suzuki K. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 385:1997;634-636.
71. Ribeyre J. M., Lesieur P., Varoquaux O., Dollfus S., Pays M., Petit M. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. Biol Psychiatry. 36:1994;230-236.
72. Ohmori T., Koyama T., Inoue T., Matsubara S., Yamashita I. B-HT 920, a dopamine D2 Agonist, in the treatment of Negative Symptom of chronic schizophrenia. Biol Psychiatry. 33:1993;687-693.
73. Kane J. M., Mayerhoff D. Do negative symptoms respond to pharmacological treatment? Symposium: Negative symptoms in schizophrenia. Br J Psychiatry. 155:1989;115-118.
74. Levi-Minzi S., Bermanzohn P. C., Siri S. G. Bromocriptine for "negative" schizophrenia. Compr Psychiatry. 32:1991;210-216.
75. King K. J. Dopamine agonists for negative symptoms in schizophrenia. Br J Clin Pharmacol. 6:1978;541-542.
76. Paillere-Martinot M. L., Lecrubier Y., Martinot J. L., Aubin F. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry. 152:1995;130-134.
77. Lindenmayer J. P. New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatr Scand. 388:1995;15-19.
78. Frith, C. D. The cognitive neuropsychology of schizophrenia. Hove, Lawrence Erlbaum Associate Ltd, 1992.
79. Hemsley D. R. Cognitive impairment in schizophrenia. Burton A. The Pathology and Psychology of Cognition. 1982;169-203 Methuen, London.
80. Rosenbaum G., MacKavey W. R., Grisell J. L. Effects of biological and social motivation in schizophrenia reaction time. J Abnorm Soc Psychol. 53:1957;364-368.
81. Liddle P. F., Morris D. L. Schizophrenia Syndromes and Frontal Lobe performance. Br J Psychiatry. 158:1991;340-345.
82. Miller E. Verbal fluency as a function of measure of verbal intelligence and in relation to different types of cerebral pathology. Br J Clin Psychol. 23:1984;53-57.
83. Wilkin A., Sanfilipo M., Wolf A. P., Angrist B., Brodie J. D., Rostrosen J. Negative symptoms and hypofrontality in chronic schizophrenia. Br J Clin Psychol. 49:1992;959-965.
84. Volkow N. D., Wolf A. P., Van Gelder P. Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia. Am J Psychiatry. 144:1987;151-158.
85. Weinberger D. R., Berman K. F., Zec R. F. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: 1 Regional cerebral blood flow (RCBF) evidence. Arch Gen Psychiatry. 43:1986;114-125.
86. Liddle P. F., Friston K. J., Frith C. D., Frockowiak R. S. Cerebral blood flow and mental processes in schizophrenia. J R Soc Med. 85:1992;224-227.
87. Bilder R. M., Lieberman J. A., Kim Y., Alvier J. M., Reiter G. Methylphenidate and neurological effects on oral word production in schizophrenia. Neuropsychiatry Neuropsychol Behav Neurol. 5:1992;262-271.
88. Daniel D. G., Weinberger D. R., Jones D. W. The effects of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci. 11:1991;1907-1917.
89. Marsden C. D. The mysterious motor function of the basal ganglia: the Robert Wartenberg lecture. Neurology. 32:1980;514-539.
90. Menza M. A., Golbe L. I., Cody R. A., Forman N. E. Dopamine-related personality traits in Parkinson's disease. Neurology. 43 3 (part 1):1993;505-508.
91. Starkstein S. E., Mayberg H. S., Preziosi T. J., Andrezejewski P., Leiguarda R., Robinson R. G. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 4:1992;134-139.
92. Yahr M. Parkinsonism. Rowland L. P. Merritt's Textbook of Neurology. 1989;658-671 Lea and Febinger, Kent.
93. Plummer A., Earl A., Scheider J., Trapold J., Barrett W. Pharmacology of Rauwolfia alkaloids, including reserpine. Ann N Y Acad Sci. 59:1954;8-21.
94. Davis G., Williams A. C., Markey S., Ebert M., Caine E., Reichert C., Kopin I. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1:1979;249-254.
95. Langston J. W., Ballard P., Tetrud J., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
96. German D. C., Dubach M., Askari S., Speciale S. G., Bowden D. M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience. 24:1988;161-174.
97. Baik J. H., Picetti R., Saiardi A. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature. 377:1995;424-428.
98. Miyashita N., Hikosaka O., Kato M. T. I. Visual hemineglect induced by unilateral striatal dopamine deficiency in monkeys. Neuroreport. 6:1995;1257-1260.
99. Ehringer H., Hornykiewicz O. Vertielung von Noradrenalin und Dopamine (3-hydroxytyramine) in Gehirn des Menschen und der Verhalten bei Erkrankunger des extrapyramiden Systems. Klin Wochenschr. 38:1960;1236-1239.
100. Marsden C. D. Dopamine and basal ganglia disorders in humans. Sem Neurosci. 4:1992;171-179.
101. Koller W. C. When does Parkinson's disease begin? Neurology. 42(Suppl 4):1992;27-31.
102. Brooks D. J. Detection of preclinical Parkinson's disease with PET. Neurology. 41:1991;24-27.
103. Van Praag H. M., Korf J., Lakke J. P. W. F., Schut T. Dopamine metabolism in depression, psychoses and Parkinson's Disease: The problem of the specificity of biological variables in behavior disorders. Psychol Med. 5:1975;138-146.
104. Sacks, O. Awakening. New York, Dutton, 1973.
105. Lindvall O., Sawle G., Widner H. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol. 35:1994;172-180.
106. Sawle G. V., Lindvall O., Bjorklund A., Frackowiak R. S. J., Brooks D. J. Long terms effects of foetal mesencephalic transplantation; PET evidence of graft survival 3 years from operation. Neurology. 43:1993;A179.
107. Morris R. G., Downes J. J., Evenden J. L., Sahakian B. J., Heald A., Robbin T. W. Planning and spatial working memory in Parkinson's disease. J Neurol Neurosurg Psychiatry. 51:1988;757-766.
108. Cummings J. L. Depression and Parkinson's disease. Am J Psychiatry. 149:1992;443-454.
109. Weddell R. A., Weiser R. A double-blind cross-over placebo-controlled trial of the effects of bromocriptine on psychomotor function, cognition, and mood in de novo patients with Parkinson's disease. Behav Pharmacol. 6:1995;81-91.
110. Brown R. G., Marsdsen C. D. Cognitive function in Parkinson's disease: from description to theory. TINS. 13:1990;21-29.
111. Philips S. G., Carr G. D. Cognition and the basal ganglia: a possible substrate of procedural knowledge. Can J Neurol Sci. 14:1987;381-385.
112. Playford E. D., Jenkins I. H., Passingham R. E., Nutt J., Frockowiak R. S., Brooks D. J. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol. 32:1992;151-161.
113. Lange K. W., Robbins T. W., Marsden C. D., James M., Owen A. M., Paul G. M. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology. 107:1992;394-404.
114. Le Moal M. Mesocorticolimbic dopaminergic neurons. Bloom F. E., Kupfer D. J. Psychopharmacology: The Fourth Generation of Progress. 1995;283-294 Raven Press, New York.
115. Koob G. F. The dopamine anhedonia hypothesis: a pharmacological phrenology. BehaviBrain Sci. 5:1982;63-64.
116. Blackburn J. R., Pfaus J. G., Phillips A. G. Dopamine functions in appetitive and defensive behavior. Prog Neurobiol. 39:1992;247-279.